Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan · Delayed Price · Currency is TWD

100.50

-8.50 (-7.80%)

Jul 9, 2026, 1:10 PM CST

23.31% (1Y)

Market Cap	18.15B +30.6%
Revenue (ttm)	1.76B +121.4%
Net Income	780.80M +94.8%
EPS	4.86 +72.6%
Shares Out	166.53M
PE Ratio	22.44
Forward PE	26.72
Dividend	2.00 (1.83%)
Ex-Dividend Date	Jul 6, 2026

Volume	41,000
Open	105.00
Previous Close	109.00
Day's Range	99.80 - 105.00
52-Week Range	64.10 - 154.00
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It als... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2014

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6620

Full Company Profile

Financial Performance

In 2025, Handa Pharmaceuticals's revenue was 1.73 billion, an increase of 108.17% compared to the previous year's 830.67 million. Earnings were 749.77 million, an increase of 58.60%.

Financial Statements